ACTIVE

APOTEEK GINDERBUITEN

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result36 k €-80,7 %over 1 year
Gross margin305 k €-37,3 %over 1 year
Equity111,1 k €+47,9 %over 1 year
Workforce2,6 ETP0,0 %over 1 year

Identity

Source · BCE/KBO

APOTEEK GINDERBUITEN is a Private limited company incorporated in 1985. Its registered office is in Mol. It employs on average 2,6 ETP workers (FTE).

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0426.798.515
Incorporation
24/01/1985
Legal form
Private limited company
Registered office
Ginderbuiten 119
2400 Mol · FlandreSee on map
Contributed capital
18 600,00 €
Latest accounts
31/12/2025
Average workforce
2,6 ETP
Joint committees (1)
  • 313
Signals
ProfitableLow riskPositive cashflowPositive EBITDAHealthy social debts

Financials

Source · NBB, 21 filings

Trend over 18 financial years

20252024202320222021
Income statement
Gross margin305 k €486,6 k €466,6 k €501,1 k €436,5 k €
EBITDA73,2 k €282,4 k €264,1 k €306,8 k €245,2 k €
Operating result66 k €269,4 k €253,8 k €297,5 k €234,3 k €
Net result36 k €186,4 k €183,3 k €217,4 k €172,9 k €
Balance sheet
Equity111,1 k €75,1 k €73,7 k €70,4 k €63 k €
Total assets692,2 k €665,8 k €628,1 k €659,9 k €594,1 k €
Cash115,5 k €159,2 k €153,1 k €190,7 k €153,8 k €
Debts581,1 k €590,7 k €554,4 k €589,5 k €531 k €
Other
Workforce2,6 ETP2,6 ETP2,6 ETP2,5 ETP–

Valuation

Indicative valuation

As an indication, this company is worth

between 500 k€ and 1 M€
See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

1 active · 30 ended

Active mandates

TOMKAT

Director · since 26 juin 2020 · 0848.145.531

Represented by CROUX KATHLEEN

Active

Ended mandates

KC PHARMA

Director · since 28 mars 2017 · until 26 juin 2020 · 0479.334.705

Represented by KATHLEEN CROUX

Ended
KC PHARMA

Director · since 28 mars 2017 · 0479.334.705

Represented by CROUX KATHLEEN

Ended
KC PHARMA

Manager · since 28 mars 2017 · 0479.334.705

Represented by Kathleen CROUX

Ended
PHICRO

Director · since 28 mars 2017 · until 26 juin 2020 · 0821.790.532

Represented by PHILIPPE CROUX

Ended

Full financial information

Source · NBB
202520242023202220212020
Type of accountAbridged modelAbridged modelAbridged modelAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202101/01/2020
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date24/07/202611/06/202530/05/202402/06/202319/04/202202/06/2021
General meeting19/06/202609/06/202528/05/202423/05/202315/04/202214/05/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 21 filings
ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202519/06/202624/07/2026DutchPDF
Abridged model31/12/202409/06/202511/06/2025DutchPDF
Abridged model31/12/202328/05/202430/05/2024DutchPDF
Abridged modelCorrection31/12/202223/05/202302/06/2023DutchPDF
Abridged model31/12/202223/05/202330/05/2023DutchPDF
Abridged model31/12/202115/04/202219/04/2022DutchPDF
Abridged model31/12/202014/05/202102/06/2021DutchPDF
Abridged model31/12/201912/05/202028/05/2020DutchPDF
Abridged model31/12/201825/06/201918/07/2019DutchPDF
Abridged model31/12/201711/05/201802/07/2018DutchPDF
Abridged model31/12/201612/05/201722/06/2017DutchPDF
Abridged model31/12/201513/05/201601/07/2016DutchPDF
Abridged model31/12/201408/05/201528/07/2015DutchPDF
Abridged model31/12/201309/05/201401/08/2014DutchPDF
Abridged model31/12/201210/05/201323/07/2013DutchPDF
Abridged model31/12/201111/05/201203/07/2012DutchPDF
Abridged model31/12/201013/05/201122/08/2011DutchPDF
Abridged model31/12/200926/06/201022/07/2010DutchPDF
Abridged model31/12/200827/06/200930/07/2009DutchPDF
Abridged model31/12/200728/06/200826/08/2008DutchPDF
Abridged model31/12/200630/06/200731/08/2007DutchPDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 500 k€ and 1 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

1 active · 30 ended

Active mandates

TOMKAT

Director · since 26 juin 2020 · 0848.145.531

Represented by CROUX KATHLEEN

Active

Ended mandates

KC PHARMA

Director · since 28 mars 2017 · until 26 juin 2020 · 0479.334.705

Represented by KATHLEEN CROUX

Ended
KC PHARMA

Director · since 28 mars 2017 · 0479.334.705

Represented by CROUX KATHLEEN

Ended
KC PHARMA

Manager · since 28 mars 2017 · 0479.334.705

Represented by Kathleen CROUX

Ended
PHICRO

Director · since 28 mars 2017 · until 26 juin 2020 · 0821.790.532

Represented by PHILIPPE CROUX

Ended

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Mandates13/12/2023
    STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …) - WIJZIGING RECHTSVORM - ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates10/07/2020
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates14/04/2017
    ONTSLAGEN - BENOEMINGEN - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …) - WIJZIGING RECHTSVORM
    PDF
  • Mandates29/09/2015
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates18/01/2010
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates07/09/2009
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates25/11/2003
    ONTSLAGEN - BENOEMINGEN
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 202536 k €↓
  2. 2024
    Annual accounts 2024186,4 k €↑
  3. 2023
    Annual accounts 2023183,3 k €↓
  4. 2022
    Annual accounts 2022217,4 k €↑
  5. 2021
    Annual accounts 2021172,9 k €↑
  6. 2018
    Annual accounts 20186,9 k €↓
  7. 2017
    Annual accounts 20179,3 k €↓
  8. 2016
    Annual accounts 201690,1 k €↑
  9. 2015
    Annual accounts 201543 k €↑
  10. 2014
    Annual accounts 20147,2 k €↓
  11. 2013
    Annual accounts 201370,2 k €↑
  12. 2012
    Annual accounts 201241 k €↑
  13. 2011
    Annual accounts 201113,9 k €↑
  14. 2010
    Annual accounts 20106,6 k €↓
  15. 2009
    Annual accounts 2009180,5 k €↓
  16. 2008
    Annual accounts 2008189,6 k €↓
  17. 2007
    Annual accounts 2007197,4 k €↑
  18. 2006
    Annual accounts 2006144,2 k €
  19. 24/01/1985
    IncorporationPrivate limited company